Results 81 to 90 of about 4,898 (191)
Health Science Reports, Volume 9, Issue 4, April 2026.ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov +7 more
wiley +1 more source
A Survey of the Microbiome, Culturome and ARG Profile of a Cohort of Chronic Diabetic Foot Lesions
APMIS, Volume 134, Issue 4, April 2026.ABSTRACT This study aimed to analyse the microbiome of chronic infected diabetic foot ulcers (DFUs) using parallel methods: traditional culture (the culturome), 16S rRNA gene sequencing (the microbiome) as well as the Antibiotic Resistance Gene (ARG) profile of isolated strains. Swab samples were collected in parallel from affected ulcers.
Karolina I. Pyrzanowska +9 more
wiley +1 more source
Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study [PDF]
Cornelius J Clancy,1 Oliver A Cornely,2– 4 Stephen W Marcella,5 Sean T Nguyen,6 Laurence Gozalo,7 Bin Cai8 1Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Institute of Translational Research, Cologne Excellence Cluster on ...
Cai B +5 more
core +1 more source
Cefiderocol in Combating Carbapenem-Resistant Acinetobacter baumannii: Action and Resistance [PDF]
Acinetobacter baumannii (A. baumannii) has emerged as a prominent multidrug-resistant (MDR) pathogen, significantly complicating treatment strategies due to its formidable resistance mechanisms, particularly against carbapenems.
Shima Asli +10 more
core +1 more source
In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii
Microbiology SpectrumThe emergence and spread of third-/fourth-generation cephalosporin and/or carbapenem-resistant Acinetobacter baumannii have become a significant global public health concern, making new treatment alternatives necessary.
Barbara Ymaña +20 more
doaj +1 more source
ChemMedChem, Volume 21, Issue 2, January 2026.This article focuses on the interplay of absorbed, distributed, metabolized, and excreted (ADME) properties; in vivo pharmacokinetics (PK); and pharmacodynamics (PD) supported by in silico PK/PD modeling techniques to improve drug development by acceleration of processes and reducing attrition risks.
Katharina Rox
wiley +1 more source
Microbiology SpectrumCefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR ...
John H. Kimbrough +8 more
doaj +1 more source
BioMed Research International, Volume 2026, Issue 1, 2026.Acinetobacter baumannii is a globally prevalent Gram‐negative pathogen responsible for a substantial proportion of healthcare‐associated infections, particularly in intensive care units. Its ability to persist in hospital environments, form biofilms on medical devices, and evade host immune responses has contributed to the rapid emergence of multidrug ...
Krupa Bhaliya +7 more
wiley +1 more source
Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak [PDF]
Variable outcomes have been reported with cefiderocol in infections due to carbapenem-resistant Acinetobacter baumannii (CRAB). Nonetheless, it may be the only option for metallo-beta-lactamase-producing strains.
Francesco Peracchi +10 more
core +1 more source
Case Reports in Critical Care, Volume 2026, Issue 1, 2026.This clinical case describes the management, in an intensive care unit (ICU), of a patient with a severe form of autism spectrum disorder (ASD) Level 3, suffering from acute respiratory failure that evolved into acute respiratory distress syndrome (ARDS).
Alessandra Ciccozzi +9 more
wiley +1 more source